Comparison of live and inactivated influenza vaccine in high risk children

Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: the Quebec Experience

“…The recent Cochrane review however reported cough in 22% (11/49) and increase in sputum production in 33% (7/21) of participants with CF in the 5 to 6 days following IIV administration. [30][31][32] These proportions are higher than what was found in our cohort, where 7% of participants reported wheezing. In our cohort, there was no difference in the risk of wheezing when those on and not on inhaled corticosteroids were compared (RR 0.23; 95% CI: 0.03, 1.75).…”

“…A Cochrane systematic review assessed influenza vaccination in 96 patients with CF; [30] only two studies used LAIV (n = 47 total) [31,32]. Gruber et al [32] showed that LAIV immunogenicity was not different in children with CF and their family members.…”

Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold‐adapted vaccine recombinant in which vaccine‐associated illness occurred in normal volunteers

“…One such potential vaccine is the Ca mutant of influenza developed by Maassab [Maassab, 19671. This virus has proven to be particularly valuable since the six "internal" genes from the Ca strain can be easily recombined with the genes coding for the current neuraminidase and hemagglutininyielding relevant vaccine [Kendal et al, 19811. Over the last several years, relevant recombinants have been undergoing investigation Hrabar et al, 1977;Murphy et al, 1981;Cate and Couch, 1982;Betts et al, 1985;Clements et al, 1986;Gorse et al, 1986;King et al, 1987;Nicholson et al, 19871. These vaccines have low rates of reactogenicity even in young children who are both hemagglutinin-and neuraminidase antibody-negative [Lazar et al , 1980;Wright et al, 1982;Belshe and VanVoris, 1984;Johnson et al, 1985;King et al, 1987).…”

Principles Underlying the Development and Use of Live Attenuated Cold-Adapted Influenza A and B Virus Vaccines

“…Bivalent influenza A ca reassortant virus vaccines have reactogenicity profiles similar to that of the monovalent vaccine viruses (36). The ca reassortant viruses were also found to be safe in subjects with various high-risk conditions such as HIV infection and cystic fibrosis and in the elderly with underlying cardiopulmonary disease (32,35,47,49).…”